180 related articles for article (PubMed ID: 11266816)
1. Prolonged allograft survival following ex vivo blockade of costimulatory signals B7-1/2 and CD40.
Steurer W; Oellinger R; Perwanger F; Brandacher G; Obrist P; Klima G; Margreiter R
Transplant Proc; 2001; 33(1-2):274-5. PubMed ID: 11266816
[No Abstract] [Full Text] [Related]
2. Aggressive skin allograft rejection in CD28-/- mice independent of the CD40/CD40L costimulatory pathway.
Ha J; Bingaman AW; Durham MM; Pearson TC; Larsen CP
Transpl Immunol; 2001 Oct; 9(1):13-7. PubMed ID: 11680567
[TBL] [Abstract][Full Text] [Related]
3. The role of the IL-2 pathway in costimulation blockade-resistant rejection of allografts.
Jones TR; Ha J; Williams MA; Adams AB; Durham MM; Rees PA; Cowan SR; Pearson TC; Larsen CP
J Immunol; 2002 Feb; 168(3):1123-30. PubMed ID: 11801646
[TBL] [Abstract][Full Text] [Related]
4. New insights into the interactions between T-cell costimulatory blockade and conventional immunosuppressive drugs.
Sho M; Sandner SE; Najafian N; Salama AD; Dong V; Yamada A; Kishimoto K; Harada H; Schmitt I; Sayegh MH
Ann Surg; 2002 Nov; 236(5):667-75. PubMed ID: 12409674
[TBL] [Abstract][Full Text] [Related]
5. Different costimulation signals used by CD4(+) and CD8(+) cells that independently initiate rejection of allogenic hepatocytes in mice.
Gao D; Li J; Orosz CG; Bumgardner GL
Hepatology; 2000 Nov; 32(5):1018-28. PubMed ID: 11050052
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of transplant rejection following treatment with anti-B7-2 and anti-B7-1 antibodies.
Lenschow DJ; Zeng Y; Hathcock KS; Zuckerman LA; Freeman G; Thistlethwaite JR; Gray GS; Hodes RJ; Bluestone JA
Transplantation; 1995 Nov; 60(10):1171-8. PubMed ID: 7482727
[TBL] [Abstract][Full Text] [Related]
7. Genetic characterization of strain differences in the ability to mediate CD40/CD28-independent rejection of skin allografts.
Williams MA; Trambley J; Ha J; Adams AB; Durham MM; Rees P; Cowan SR; Pearson TC; Larsen CP
J Immunol; 2000 Dec; 165(12):6849-57. PubMed ID: 11120808
[TBL] [Abstract][Full Text] [Related]
8. Transplantation and the CD28/CTLA4/B7 pathway.
Alegre M; Fallarino F; Zhou P; Frauwirth K; Thistlethwaite J; Newell K; Gajewski T; Bluestone J
Transplant Proc; 2001; 33(1-2):209-11. PubMed ID: 11266782
[No Abstract] [Full Text] [Related]
9. Blockade of the CD28/B7 pathway is required for the establishment of donor cell chimerism in CD40 ligand-deficient recipients.
Woodward JE; Zottola LB; Schaefer AT; Logar AJ; Stazer JK; Daskivich T; Peach R; Rao AS
Transplant Proc; 2001; 33(1-2):115. PubMed ID: 11266734
[No Abstract] [Full Text] [Related]
10. Comparative strategies to induce long-term graft acceptance in fully allogeneic renal versus cardiac allograft models by CD28-B7 T cell costimulatory blockade: role of thymus and spleen.
Schaub M; Stadlbauer TH; Chandraker A; Vella JP; Turka LA; Sayegh MH
J Am Soc Nephrol; 1998 May; 9(5):891-8. PubMed ID: 9596088
[TBL] [Abstract][Full Text] [Related]
11. Blockade of costimulatory molecules on dendritic cells: implications for tolerance induction.
Luke PP; Thomson AW
Transplant Proc; 2001; 33(1-2):507-8. PubMed ID: 11266929
[No Abstract] [Full Text] [Related]
12. CD4-targeted therapy and CD28-B7 costimulatory blockage may independently induce tolerance in sensitized allograft recipients.
Kato H; Onodera K; Chandraker A; Volk HD; Sayegh MH; Kupiec-Weglinski JW
Transplant Proc; 1998 Jun; 30(4):1063-4. PubMed ID: 9636430
[No Abstract] [Full Text] [Related]
13. Host CD40 ligand deficiency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis.
Shimizu K; Schönbeck U; Mach F; Libby P; Mitchell RN
J Immunol; 2000 Sep; 165(6):3506-18. PubMed ID: 10975872
[TBL] [Abstract][Full Text] [Related]
14. CTLA4-Ig inhibits rejection of mouse liver allografts from Flt3-ligand-treated donors and is associated with increased lymphocyte apoptosis.
Li W; Lu L; Wang Z; Wang L; Thomson A; Fung J; Qian S
Transplant Proc; 2001; 33(1-2):246-7. PubMed ID: 11266801
[No Abstract] [Full Text] [Related]
15. Systemic administration of CTLA4-Ig or anti-CD40 ligand antibody inhibits second-set rejection of mouse liver allografts.
Fu F; Li W; Lu L; Thomson AW; Fung JJ; Qian S
Transplant Proc; 1999; 31(1-2):1244. PubMed ID: 10083555
[No Abstract] [Full Text] [Related]
16. Treatment of allograft recipients with donor-specific transfusion and anti-CD154 antibody leads to deletion of alloreactive CD8+ T cells and prolonged graft survival in a CTLA4-dependent manner.
Iwakoshi NN; Mordes JP; Markees TG; Phillips NE; Rossini AA; Greiner DL
J Immunol; 2000 Jan; 164(1):512-21. PubMed ID: 10605049
[TBL] [Abstract][Full Text] [Related]
17. Blockade of the B7-CD28 pathway by CTLA4-Ig counteracts rejection and prolongs survival in small bowel transplantation.
Kurlberg G; Haglind E; Schön K; Törnqvist H; Lycke N
Scand J Immunol; 2000 Mar; 51(3):224-30. PubMed ID: 10736090
[TBL] [Abstract][Full Text] [Related]
18. CD28-independent costimulation of T cells in alloimmune responses.
Yamada A; Kishimoto K; Dong VM; Sho M; Salama AD; Anosova NG; Benichou G; Mandelbrot DA; Sharpe AH; Turka LA; Auchincloss H; Sayegh MH
J Immunol; 2001 Jul; 167(1):140-6. PubMed ID: 11418642
[TBL] [Abstract][Full Text] [Related]
19. The time course of CTLAIg effect on cardiac allograft rejection.
Bolling SF; Lin H; Turka LA
J Surg Res; 1996 Jun; 63(1):320-3. PubMed ID: 8661218
[TBL] [Abstract][Full Text] [Related]
20. Prevention of T-cell activation by rhCTLA4-Ig and anti-CD40L monoclonal antibody results in indefinite islet allograft survival.
Rastellini C; Salam A; Kuddus R; Aitouche A; Subbotin V; Braun M; Leach R; Peach R; Fung JJ; Starzl TE; Rao AS
Transplant Proc; 1999; 31(1-2):1242-3. PubMed ID: 10083554
[No Abstract] [Full Text] [Related]
[Next] [New Search]
